Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics

Fig. 4

Changes in plasma amyloid-β 1–42 peptide (Aβ1–42) concentration in subjects who received oral doses of the β-site amyloid precursor protein cleaving enzyme 1inhibitor LY2886721 in separate clinical studies. a Mean percentage change in Aβ1–42 concentration from baseline values for subjects treated with single doses of LY2886721 in study I4O-MC-BACA. b Plasma Aβ1–42 concentration for individual subjects treated with 14 consecutive once-daily doses of LY2886721 in study I4O-MC-BACB. Samples from both studies were quantified with Fujirebio Aβ1–42 peptide standard

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193